Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
EGR2 is an epigenomic regulator of phagocytosis and antifungal immunity in alveolar macrophages
Zsuzsanna Kolostyak, Dora Bojcsuk, Viktoria Baksa, Zsuzsa Mathene Szigeti, Krisztian Bene, Zsolt Czimmerer, Pal Boto, Lina Fadel, Szilard Poliska, Laszlo Halasz, Petros Tzerpos, Wilhelm K. Berger, Andres Villabona-Rueda, Zsofia Varga, Tunde Kovacs, Andreas Patsalos, Attila Pap, Gyorgy Vamosi, Peter Bai, Balazs Dezso, Matthew Spite, Franco R. D’Alessio, Istvan Szatmari, Laszlo Nagy
Zsuzsanna Kolostyak, Dora Bojcsuk, Viktoria Baksa, Zsuzsa Mathene Szigeti, Krisztian Bene, Zsolt Czimmerer, Pal Boto, Lina Fadel, Szilard Poliska, Laszlo Halasz, Petros Tzerpos, Wilhelm K. Berger, Andres Villabona-Rueda, Zsofia Varga, Tunde Kovacs, Andreas Patsalos, Attila Pap, Gyorgy Vamosi, Peter Bai, Balazs Dezso, Matthew Spite, Franco R. D’Alessio, Istvan Szatmari, Laszlo Nagy
View: Text | PDF
Research Article Infectious disease Inflammation

EGR2 is an epigenomic regulator of phagocytosis and antifungal immunity in alveolar macrophages

  • Text
  • PDF
Abstract

Alveolar macrophages (AMs) act as gatekeepers of the lung’s immune responses, serving essential roles in recognizing and eliminating pathogens. The transcription factor (TF) early growth response 2 (EGR2) has been recently described as required for mature AMs in mice; however, its mechanisms of action have not been explored. Here, we identified EGR2 as an epigenomic regulator and likely direct proximal transcriptional activator in AMs using epigenomic approaches (RNA sequencing, ATAC sequencing, and CUT&RUN). The predicted direct proximal targets of EGR2 included a subset of AM identity genes and ones related to pathogen recognition, phagosome maturation, and adhesion, such as Clec7a, Atp6v0d2, Itgb2, Rhoc, and Tmsb10. We provided evidence that EGR2 deficiency led to impaired zymosan internalization and reduced the capacity to respond to Aspergillus fumigatus. Mechanistically, the lack of EGR2 altered the transcriptional response, secreted cytokines (i.e., CXCL11), and inflammation-resolving lipid mediators (i.e., RvE1) of AMs during in vivo zymosan-induced inflammation, which manifested in impaired resolution. Our findings demonstrated that EGR2 is a key proximal transcriptional activator and epigenomic bookmark in AMs responsible for select, distinct components of cell identity and a protective transcriptional and epigenomic program against fungi.

Authors

Zsuzsanna Kolostyak, Dora Bojcsuk, Viktoria Baksa, Zsuzsa Mathene Szigeti, Krisztian Bene, Zsolt Czimmerer, Pal Boto, Lina Fadel, Szilard Poliska, Laszlo Halasz, Petros Tzerpos, Wilhelm K. Berger, Andres Villabona-Rueda, Zsofia Varga, Tunde Kovacs, Andreas Patsalos, Attila Pap, Gyorgy Vamosi, Peter Bai, Balazs Dezso, Matthew Spite, Franco R. D’Alessio, Istvan Szatmari, Laszlo Nagy

×

Figure 7

Lack of EGR2 affects some gene sets primarily regulated by zymosan stimulation.

Options: View larger image (or click on image) Download as PowerPoint
Lack of EGR2 affects some gene sets primarily regulated by zymosan stimu...
(A) The proportional dot plots represent the number of the associated opening and closing DARs within the ±100 kbp region of the gene TSSs or up to the nearest gene(s) (left, highlighted in red), and the number of the EGR motifs within these ATAC-Seq peaks (right, highlighted in blue), separately for the 10 clusters’ genes presented in Figure 6D. (B) The Venn diagram portrays the overlaps of the significantly repressed genes between Egr2+/+ and Egr2fl/fl AMs upon control or 6-hour or 24-hour zymosan treatment. The highlighted 436 genes present a zymosan-dependent repressed gene set. (C) The bar chart represents the distance distribution of the EGR motif–containing (purple) or –noncontaining (gray) closing DARs (n = 1,075, which are located farther from the repressed genes than 1,000 kbp in Figure 2B) relative to the TSS position of the repressed zymosan-dependent DEGs (n = 436). (D and E) The IGV snapshots show (D) the ATAC-Seq coverages of Egr2+/+ and Egr2fl/fl AM samples in control and in the presence of the EGR motif(s) related to 4 selected genes, (E) the coverages of which are shown in panel D in the control and 6- and 24-hour zymosan-treated Egr2+/+ and Egr2fl/fl AMs in RNA-Seq (overlaid). (F and G) Bar graphs show the (mean ± SEM) values of normalized mRNA level of Arhgap10 gene (F) and the Arhgap10-related region’s eRNA in the control and ex vivo 6- and 24-hour zymosan-treated Egr2+/+ and Egr2fl/fl AMs (t test, *P ≤ 0.05, **P ≤ 0.01).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts